Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Fuji
McKinsey
Mallinckrodt
McKesson
Fish and Richardson
Citi
US Department of Justice
Daiichi Sankyo
Deloitte

Generated: October 23, 2017

DrugPatentWatch Database Preview

KERYX BIOPHARMS Company Profile

« Back to Dashboard

What is the competitive landscape for KERYX BIOPHARMS, and what generic alternatives to KERYX BIOPHARMS drugs are available?

KERYX BIOPHARMS has one approved drug.

There are fourteen US patents protecting KERYX BIOPHARMS drugs.

There are one hundred and twelve patent family members on KERYX BIOPHARMS drugs in twenty-six countries.

Summary for Applicant: KERYX BIOPHARMS

International Patents:112
US Patents:14
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Keryx Biopharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Keryx Biopharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,750,715Method of reversing, preventing, delaying or stabilizing soft tissue calcification► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Keryx Biopharms Drugs

Country Document Number Estimated Expiration
Canada2640974► Subscribe
Australia2004213819► Subscribe
Taiwan201412308► Subscribe
Japan2013177416► Subscribe
Denmark0959878► Subscribe
Australia723091► Subscribe
Taiwan201711676► Subscribe
European Patent Office3066923► Subscribe
Taiwan201544102► Subscribe
Hong Kong1077580► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
AstraZeneca
Queensland Health
Cerilliant
Dow
McKesson
Teva
Cantor Fitzgerald
Chubb
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot